COVID-19 and the brain: Meyer and colleagues provide a systematic review of current literature on the applications and findings of molecular imaging techniques in elucidating the effects of COVID-19 on the human brain. ................. Page 971

Alzheimer disease standards of care: Teipel and colleagues summarize standards of diagnosis (including advances in molecular imaging), treatment, care, and prevention of Alzheimer disease. .......................... Page 981

Radiotracers in cardiovascular imaging: Stendiahl and colleagues highlight current and promising radiotracers for imaging cardiovascular inflammation, thrombosis, fibrosis, calcification, and amyloidosis, with a focus on addressing unmet clinical needs. .......................... Page 986

Women authors in nuclear medicine journals: Lasnon and colleagues evaluate recent trends in the gender distribution of first and last authorship of articles published in nuclear medicine journals. .......................... Page 995

PET and DLBCL response prediction: Burggraaff and colleagues explore the value added by baseline metabolic tumor volume and interim PET to conventional prognostic indices for 2-y progression-free survival in diffuse large B-cell lymphoma and investigate optimal interim PET response criteria. .......................... Page 1001

18F-FDG PET molecular signatures in MM: Alberge and colleagues identify gene expression patterns associated with prognostic 18F-FDG PET biomarkers in newly diagnosed multiple myeloma patients included in the prospective multicenter CASSIOPET study. .......................... Page 1008

PET tumor burden and NET prognosis: Thullier and colleagues investigate the prognostic value of somatostatin receptor tumor burden on 68Ga-DOTATOC PET/CT in patients with well-differentiated neuroendocrine tumors. .......................... Page 1014

FApi PET versus FAP IHC: Mona and colleagues report on the spectrum of fibroblast-activation protein expression across various cancers by immunohistochemistry and explore whether 68Ga–FAP inhibitor–46 PET biodistribution accurately reflects FAP expression from resected cancer and noncancer specimens. .......................... Page 1021

68Ga-DOTATATE PET FTV in NETs: Reddy and colleagues compare multiple PET functional tumor volume computational approaches and morphologic volume measurements to identify a candidate date for incorporation into 68Ga-DOTATATE PET FTV studies and more accurately assess neuroendocrine tumor burden. .......................... Page 1027

GPC3-targeted 227Th therapy for HCC: Labadie and colleagues describe the development and in vivo efficacy of a 227Th-labeled glycoprotein-3–targeting antibody conjugate for treatment of hepatocellular carcinoma in an orthotopic murine model. .......................... Page 1033

Enhancing 223Ra efficacy: Paindelli and colleagues test the effect of a cotargeting strategy combining 223Ra and anti-β1 integrin antibody treatment in PC3 and C4-2B prostate cancer cell models expressing high and low β1 integrin levels. .......................... Page 1039

Pretargeting and trastuzumab combination: Oroujeni and colleagues test in mice a combination of Affibody-based peptide nucleic acid–mediated pretargeted radionuclide therapy and trastuzumab treatment of HER2-expressing xenografts to extend survival. .......................... Page 1046

18F-flortaucipir PET in PSP: Malpetti and colleagues use a data-driven approach to determine whether postmortem pathologic staging in progressive supranuclear palsy can be reproduced in vivo with 18F-flortaucipir PET. .......................... Page 1052

Cognition and 18F-FDG PET in long COVID: Dressing and colleagues assess cognitive profiles and the potential of regional cerebral glucose metabolism as a biomarker of neuronal function in patients with long-term neurocognitive symptoms after COVID-19. .......................... Page 1058

11C-PiB PET in AL cardiac amyloidosis: Choi and colleagues determine the independent prognostic value of 11C-Pittsburgh compound B PET/CT in staging and risk assessment in patients with amyloid light-chain cardiac amyloidosis. .......................... Page 1064

V/P scintigraphy in COVID-19: Le Roux and colleagues evaluate the role of ventilation imaging when lung scintigraphy is performed because of suspected pulmonary embolism in COVID-19 patients and describe associated practices and imaging findings in this population. .......................... Page 1070

90Y radioembolization lung dose and toxicity: Stella and colleagues characterize the relationship between lung dose and eventual occurrence of radiation pneumonitis in patients after 90Y-microparticle liver radioembolization. .......................... Page 1075

18F-FCH PET/CT in PHT: Boudousq and colleagues compare contrast-enhanced 18F-fluorocholine PET/CT, cervical ultrasonography, and conventional scintigraphic imaging, combined and individually, for preoperative localization of hyperfunctional parathyroids in patients with primary hyperparathyroidism. .......................... Page 1081

PET/CT cervical cancer radiomics: Yusufaly and colleagues develop and validate a model incorporating nontumor PET/CT radiomics, including whole-body features, to predict treatment outcomes in patients with previously untreated locoregionally advanced cervical cancer. .......................... Page 1087

124I-Omburtamab in DSRCT: Grkovic and colleagues use serial PET/CT to assess the pharmacokinetics, biodistribution, and radiation dosimetry of 124I-Omburtamab administered intraperitoneally in patients with desmoplastic small round cell tumors. .......................... Page 1094

90Y total-body PET TARE dosimetry: Costa and colleagues assess the suitability of the total-body PET/CT eXPLORER for imaging 90Y-microsphere transarterial radioembolization and investigate possible improvements in associated PET-based dosimetry. .......................... Page 1101

Toward patient-specific kidney phantoms: Theisen and colleagues present a methodology for designing single-compartment kidney phantoms for SPECT/CT that mimic inhomogeneous spatial activity distributions, with potential for reducing uncertainties in planning and monitoring individualized radionuclide therapies. .......................... Page 1108

PET drug workshop: Bunning and participants detail the proceedings of a workshop on inspections management and regulatory considerations for radiopharmaceuticals held in 2020 at the U.S. Food and Drug Administration. .......................... Page 1117